Positive Health Online

Abstract

FLORES and COLLEAGUES, 1 Nutrition and Food Science Program, University of Granada, Spain; 2 Nutrition and Dietetics, Faculty of Medical Sciences, Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, 150950; 3 Carrera de Enfermería, Facultad de Ciencias Sociales y de la Salud, Universidad Estatal de Santa Elena, Santa Elena, Ecuador, 241702; 4 Carrera de Medicina, Facultad de Ciencias Médicas, Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, 150950; 5 Servicio de Nefrología, Hospital Central Dr. Urquinaona, Facultad de Medicina, Universidad de Zulia, Maracaibo, Venezuela, 4001; 6 Instituto de Investigación e Innovación de Salud Integral, Universidad Católica de Santiago de Guayaquil, Avenue Carlos Julio Arosemena Tola, Guayaquil, Ecuador; 7 Escuela de Nutrición y Dietética, Universidad Espíritu Santo-Ecuador, Avenue Samborondón, Guayaquil, Ecuador; 8 Department of Physiology, Institute of Nutrition and Food Technology, University of Granada, Granada, Spain, 18010 present results of a prospective, randomized, double-blind study in patients with CKD undergoing haemodialysis.

Background

Chronic kidney disease (CKD) is an increasingly common public health problem that increases the risk of death because of cardiovascular complications by 2-3 times compared with the general population.

Methodology

This research concerns a prospective, randomized, double-blind study in patients with CKD undergoing haemodialysis. The participants were assigned to 1 of 2 groups: the study group (group A; 46 patients) received 4 capsules (2.4 g) of omega-3 fatty acids daily during the 12-week intervention, while patients in the control group (group B; 47 patients) received 4 capsules of paraffin oil. The patients' general characteristics, nutritional indicators, renal disease markers and inflammatory markers (C-reactive protein, interleukin (IL)-6, IL-10, and tumour necrosis factor alpha (TNF-α)) were evaluated.

Results

No differences were found between the general characteristics of the patients (P < 0.05), and no differences were shown in the nutritional indicators and markers of kidney disease (P < 0.05). Patients in group A showed significant decreases in levels of C-reactive protein, IL-6, TNF-α, and the IL-10/IL-6 ratio after 12 weeks of supplementation (P < 0.05). Patients in group B did not show any significant changes in concentrations of inflammatory markers during the intervention (P < 0.05).

Conclusion

In conclusion, oral supplementation with omega-3 fatty acids produces a significant decrease in the concentrations of inflammation markers in patients with chronic kidney disease on haemodialysis. Novelty Oral supplementation with omega-3 fatty acids produced significant decreases in the concentrations of inflammation markers. This supplementation could be given to patients with uremic syndrome and coronary heart disease to reduce cardiovascular risk.

References

José A Valle Flores  1   2 , Juan E Fariño Cortéz  3 , Gabriel A Mayner Tresol  4 , Juan Perozo Romero  5 , Miquel Blasco Carlos  6   7 , Teresa Nestares 8. Oral supplementation with omega-3 fatty acids and inflammation markers in patients with chronic kidney disease in hemodialysis  Appl Physiol Nutr Metab.;45(8):805-811.  Aug 2020. doi: 10.1139/apnm-2019-0729. Epub Jan 14 2020 .

Comment

The above research demonstrated that oral supplementation with omega-3 fatty acids in patients with chronic kidney disease on haemodialysis produced a significant decrease in inflammation marker concentrations, suggesting that such supplements reduce cardiovascular risk in patients with uremic syndrome and coronary heart disease.